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Introduction
Despite progress, multiple myeloma remains largely incurable, 
recruiting relapses from genetically heterogeneous multiple mye­
loma subclones (1, 2). Cytopenias from cumulative treatment 
toxicity and refractory multiple myeloma limit therapeutic 
options and lifespan creating need for bone marrow sparing 
approaches effective against genetically highly variable myeloma 
cell populations.
Defense against stress misfolded proteins exert on the endo­
plasmic reticulum (ER) has been identified as Achilles heel of
multiple myeloma (3). Proteins destined for secretion enter the 
ER in an incompletely folded state and factors commonly found 
in cancer, like augmented protein synthesis, nutrient deficiency, 
and hypoxia increase them or impair their folding exerting ER 
stress (4). In multiple myeloma, high protein synthesis related to 
neoplastic behavior is amplified by plasma cell program activa­
tion yielding the highest protein secretion rate known in mam­
malian biology (5). Furthermore, secreted antibodies have com­
plex folding needs involving correct arrangement of multiple 
intra- and intermolecular disulfide bonds (5, 6). If misfolded 
proteins accumulate in the ER gradually induction of the tran­
scription factor CHOP (C∕EBP homologous protein) triggers 
suicide (4) whereas acute misfolding events like severe hypoxia 
cause apoptosis via opening of ER calcium channels (7). One way 
cells attempt to evade such fate is by transport of misfolded ER 
proteins into the cytoplasm for ubiquitination and proteasomal 
degradation (8, 9). Interference with disposal of naturally occur­
ring misfolded antibodies appears critical for clinical success of 
the proteasome inhibitor bortezomib in multiple myeloma (10, 
11), suggesting a blockade of the folding mechanism could 
further improve multiple myeloma therapy. Only the family of 
protein disulfide isomerases (PDI), which contains 17 members 
with 1-4 active CXXC or CXXC-like motifs (12), can accomplish 
correct arrangement of disulfide bonds in the ER through reduc­
tase, oxidase, and isomerase functions.
To streamline selection of anti-multiple myeloma drug candi­
dates for further study, we chose a mechanistically unbiased 
approach and filtered compounds by assessment in one
multilayered assay modeling major barriers to clinical success; 
liver metabolism, need for diffusion, transient exposure, myelo­
ma-supporting niche, and bone marrow toxicity. The lead com­
pound (CCF642) had broad anti-multiple myeloma activity, was 
effective in vivo, and appeared to act, at least in part, by inhibition 
of PDI through a novel mechanism. Here we describe the discov­
ery and initial characterization of CCF642.
Materials and Methods
Cells
RPMI 8226, NCI-H929, MM1.S, MM1.R, U266, Jeko-1, Rec-1, 
Mino, JVM-2, SU-DHL-6, SU-DHL-16, I<562, K<G-1, GDM-1, and 
HS-5 were from ATCC (authenticated there by STR). KMS-12-PE 
and KMS-12-BM were from JCRB (authenticated there by STR) 
and JJN-3 from DSMZ (authenticated there by multiplex PCR of 
minisatellite markers). 5TGMl-luc mouse multiple myeloma 
cells were kindly provided by Dr. Babatunde O. Oyajobi, Univer­
sity of Texas Health Science Center at San Antonio (San Antonio, 
TX), where this cell line was discovered and characterized (13- 
16). All of the above cells were kept in culture for less than 6 
months including expansion for aliquot freezing. HRMM.09 cells 
were established from blood of a patient with secondary plasma 
cell leukemia under Institutional Review Board (IRB)-approved 
consent in our laboratory. MMl.S-luc, HRMM.09-luc, and NCI- 
H292-luc were transduced with firefly luciferase lentivirus (Qia- 
gen), not further authenticated, but used within 6 months after 
luciferase expression confirmation. Anti-CD138 magnetic bead- 
purified peripheral blood plasma cells from two patients with 
secondary plasma cell leukemia (sPCL-l, -2) who consented to an 
IRB-approved sample collection protocol were used after 4 weeks 
in culture and one Ficoll density centrifugation to remove dead 
cells. Normal bone marrow mononuclear (NLBM) cells were from 
discarded bags of bone marrow grafts from healthy stem cell 
donors under an IRB-approved consent waiver. Human multiple 
myeloma cells were grown in RPMI 1640, 5TGM1-luc in IMDM, 
HS-5 in DMEM, and NLBM cells in RPMI supplemented with 25% 
(v∕v) of supernatant removed from confluent HS-5 cell cultures; 
all media was supplemented with 10% FBS, penicillin G (50 units/ 
mL), and streptomycin (50 μg∕mL). All cells cultured at 37°C, 5% 
CO2 in humidified air.
Primary screen
A total of 30,335 chemically diverse small molecules were 
screened for anti-multiple myeloma activity in MM 1 .S cells using 
a single-step cellular ATP quantitation assay (Supplementary 
Table S1 and Supplementary Methods).
Multilayered (sandwich) in vivo model
HS-5 bone marrow stromal cells were grown to confluence on 
semipermeable bottoms of 24-well Transwell inserts (Corning), 
then MMl.S-luc cells were added and cocultured overnight. The 
next day, drug candidate was suspended into C57BL∕KaLwRij 
mouse liver homogenate (preparation in Supplementary Meth­
ods), incubated at 37°C for 30 minutes, then mixed with 35-40°C 
warm low gelling temperature liquid agarose (Sigma-Aldrich), 
and immediately dispensed into 24-well plates where it was 
allowed to solidify at room temperature for 30 minutes. NLBM 
cells were layered on top and left there, whereas HS-5∕MMl.S-luc 
cell containing inserts were moved after 1 to 3 hours with about 
25% of the drug-equilibrated media in them into drug-free liver/
agarose/media wells to decrease concentrations of drugs by esti­
mated 75% once a new equilibrium is reached, assuming no liver 
metabolism occurs. Three to 4 days later, multiple myeloma 
luciferase activity was measured after addition of firefly D-lucif- 
erin, 0.5 mg/mL (Gold Biotechnology), and viability of aspirated 
NLBM cells was assessed by trypan blue exclusion using Vicell flow 
(Beckman Coulter).
Medicinal chemistry
CCF642, biotinylated CCF642 (B-CCF642), and CCF642- 
COOH were synthesized in our laboratories. Synthetic schemes 
and graphs confirming their identity by 1H-NMR and mass 
spectrometry are in Supplementary Methods and Fig. S1, 
respectively.
PDI activity
PDI activity was measured according to a published protocol 
using di-eosin-diglutathione (di-E-GSSG) as pseudo substrate for 
sensitive assessment of PDFs reductase activity (17) with minor 
modifications and details in Supplementary Methods.
Computational modeling and molecular dynamics
The computational model used the reduced PDI (NP_000909.2) 
crystal structure (18), as binding of biotinylated CCF642 to PDI was 
enhanced after reduction with dithiothreitol (DTT). Docking of 
CCF642 on PDI (PDB ID: 4EKZ) used Autodock 4.1 (in Autodock 
Tools 1.5.2). Binding energy calculations used CHARMM force field 
in Discovery Studio 1.3 pipeline (Accelrys, Inc.). Final image 
processing and electrostatic surface potential calculation used 
Pymol (www.pymol.org).
Single-cell cytoplasmic calcium measurements
MM 1 .S cells were loaded with Fura 2-AM and dynamic changes 
in cytoplasmic calcium concentration were measured by single-
cell digital imaging as described previously in detail (19).
PDIA1 site-directed mutagenesis
Human cDNA clone NM_000918 (Origene) was subcloned 
from pCMV6-XL4 into pT7CFEl-CHis (Thermo Fisher Scientific) 
for site-directed mutagenesis (primer sequences in Supplemen­
tary Methods) using QuikChange II XL (Agilent Technologies). 
Proteins were purified with His-tagged purification miniprep-kit 
(Clontech).
Protein S-nitrosylation
Protein S-nitrosylation was investigated via biotin switch meth­
od using Cayman Chemical kit (cat.# 10006518) according to 
manufacturer's instructions.
Genotoxicity screen
Genotoxicity screen used SOS chromotest kit with S9 rat liver 
enzymes (ebpi) according to manufacturer's instructions.
Animal experiments
Animal experiments were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals of the NIH, 
and conducted under an approved Institutional Animal Care and 
Use Committee protocol. C57BL∕KaLwRij mice (Harlan Laborato­
ries) of 6 to 8 weeks of age were injected with 5TGM1-luc cells via 
tail vein the day before drug treatments were started. CCF642 
was administered as albumin formulation intraperitoneally,
bortezomib in PBS subcutaneously. Life imaging using Xenogen 
IVIS CCD was performed 7 minutes after subcutaneous injection of 
luciferin (Gold Biotechnology). Statistical analysis used JMP 10.0.X 
software (SAS Institute, Inc.). Retro-orbital plexus blood draws 
were done after isoflurane (3%) inhalation anesthesia and com­
plete blood counts obtained on Hemavet 950FS (Drew Scientific), 
which gives mouse reference values; plasma biochemical tests were 
analyzed on cobas c311 (Roche Diagnostics) with gender specific 
biochemical reference values from C57B1∕6J mice (20) as reference.
Figure 1.
Schema of small-molecule screening algorithm. The in vivo model exposes 
NLBM constantly to small molecule (sm)-emitting liver, whereas luciferase- 
expressing MM1.S-luc cells, grown on resistance-conferring HS-5 bone 
marrow stroma cells in Transwell inserts, are exposed for 1 to 3 hours before 
they are placed with drug-equilibrated insert media (about 25% of well 
volume) into wells containing drug-free liver and NLBM with 75% small 
molecule-free media to simulate rapid single-dose clearance and the natural 
microenvironment. Three to 4 days later, drug-exposed NLBM cells are 
aspirated and analyzed by trypan blue flow cytometry, whereas MM1.S-luc 
survival is assessed by luminescence. The primary cytotoxicity screen and 
multiple myeloma cell line panel uses conventional constant small molecule 
exposure, with cellular ATP measurement and trypan blue flow cytometry 
after 3 to 4 days as readout of surviving cells, respectively.
Results
Mechanistically unbiased discovery of antimyeloma compound 
CCF642
To identify new clinically translatable treatments for the incur­
able cancer multiple myeloma that disrupt critical programs for 
this malignancy while sparing normal bone marrow, we used a 
mechanistically unbiased algorithm on a library of 30,335 small 
molecules (Fig. 1). The first step tested for anti-multiple myeloma 
activity. It identified 225 compounds that suppressed cellular ATP 
in MM1.S cells to ≤30% of vehicle control at <5 μmol∕L after 3 to 
4 days (Fig. 1 and Supplementary Table S1). Step two sought to 
filter these 225 agents for clinical promise in terms of relative 
tolerance by NLBM and ability to overcome pharmacokinetic and
pharmacodynamic barriers to anti-multiple myeloma activity. 
Emitted from agarose-embedded liver homogenate that was able 
to reduce the activity of hepatically metabolized bortezomib 
(Supplementary Fig. S2); only three drug candidates demonstrated 
promising anti-multiple myeloma activity in a setup that included 
resistance conferring HS-5 bone marrow stroma cells (21) as niche 
and a method to decrease drug concentrations through non- 
hepatic means after 90 minutes by transfer of MMl.S-luc/HS-5 
containing semipermeable inserts into drug-free liver/agarose/ 
media containing wells. None of the three hits inhibited the 
number of surviving NLBM cells by more than 30%, although 
they were exposed to drug-emitting liver constantly for 4 days 
(Figs. 1 and 2B). Bortezomib, known to be relatively well tolerated 
by normal bone marrow at doses needed to control multiple 
myeloma, had a similar therapeutic window in this assay (Fig. 2B).
In the third step, we tested whether compounds targeted 
programs of general importance in multiple myeloma via cyto­
toxicity assessment in a cell line panel. All three hits of step 2 had 
sub- or low micromolar IC50 (<5 μmol∕L) against all of at least 
seven genetically heterogeneous multiple myeloma cell lines 
tested per compound using trypan blue flow cytometry with 
constant exposure over 72 hours (Fig. 2C). CCF642 was most 
potent with submicromolar IC50 in 10 of 10 multiple myeloma 
cell lines tested (Fig. 2C).
Step four asked whether the in vivo model indeed yielded 
molecules with in vivo activity. To this end, we used an aggressive 
syngeneic mouse model of myeloma (15) that causes typical 
myeloma bone disease and death of C57BL∕KaLwRij mice about 
1 to 2 months after tail vein injection of luciferase expressing 
5TGM1 cells (5TGMl-luc). 5TGMl-luc mouse multiple myeloma 
cells were included in the otherwise human multiple myeloma 
cell line panel (Fig. 2C) to ensure the target was expressed in mice 
as well. Limited solubility could be addressed by dissolving 
DMSO stock of CCF642 and CCF1172 into albumin solution, 
which had no toxicity as vehicle on multiple myeloma cells and 
did not affect potency of hits against multiple myeloma cells in 
vitro, but the best solution we identified for CCF1118, 0.8% 
Tween-20 in sterile water, did not allow dosing above 4 mg∕kg. 
With these limitations in mind, CCF642 at 10 mg/kg intraperi- 
toneally three times a week yielded most convincing therapeutic 
effects, significantly prolonging life of 5TGMl-luc-bearing mice 
and suppressing 5TGM1 -luc growth as determined by life imaging 
(Fig. 2D). We therefore concentrated on CCF642 and initially 
evaluated cytotoxicity against other hematologic malignancies, 
which revealed similar IC50 in ontogenetically related lymphoma, 
whereas a three-cell line screening sample of myeloid neoplasia 
showed more varied responsiveness. Primary cells from patients 
with refractory myeloma who developed secondary plasma cell 
leukemia (sPCL) also had IC50 below 1 μmol/L, whereas three 
separate NLBM samples confirmed NLBM tolerance up to 6.75 
μmol∕L, the maximal dose tested (Supplementary Fig. S3).
Next, we compared CCF642 to the most potent FDA-approved 
upfront drug for myeloma, bortezomib. CCF642 at 10 mg/kg 
intraperitoneally three times a week significantly improved life-
span of mice compared with albumin vehicle. Bortezomib given 
at the MTD for this mouse strain (0.6 mg/kg subcutaneously twice 
a week) yielded similar prolongation of life, not statistically 
different from CCF642 (P = 0.18, log-rank test), and life imaging 
on day 23 documented comparable significant suppression of 
5TGMl-luc growth. Treatments appeared to be well-tolerated on 
the basis of normal behavior and stable weights (Fig. 3A-C). To
explore safety further, blood after 15 and 28 days of treatment 
from five additional 5TGM1 -luc-bearing mice per time point was 
obtained to screen for toxicity on bone marrow (blood counts), 
liver (alanine aminotransferase, ALT), kidney (creatinine), and 
effects on glucose metabolism. Except for asymptomatic increase 
of neutrophils, parameters remained within reference range after 
CCF642 (Fig. 3D). Culture of 5TGMl-luc and MMl.S-luc cells in 
bortezomib-containing media over 6 months increased the IC50 
toward this drug but not toward CCF642 in both cell lines, 
suggesting CCF642 may prove useful in the context of bortezomib 
resistance and acts via a different mechanism (Fig. 4).
An active biotinylated analogue identifies PDI as CCF642 target 
To identify the target of CCF642, we introduced a biotin moiety 
at its 4-methoxy group (Fig. 5A) expecting this was not the target 
interaction site since a commercially available unsubstituted phe­
nyl analog retained anti-multiple myeloma activity, although IC50 
in MM1.S was increased from 0.25 to 1.8 μmol∕L. Biotinylated
CCF642 (B-CCF642) also had higher IC50 (2.9 μmol/L), but at 
6.75 μmol/L, MM1.S survival was comparable to CCF642 (<2Oo∕o 
at 72 hours), suggesting it may act intracellularly but enter less 
well. Streptavidin immunohistochemistry confirmed entry into 
the cytoplasm of MM1.S (Fig. 5B). Treatment of MM1.S cells with 
B-CCF642 followed by SDS-PAGE and biotin staining suggested 
covalent interactions are formed with a main band at around 60 
kDa (Supplementary Fig. S4). Mass spectrometry of streptavidin- 
bead purified protein lysates from B-CCF642-treated and untreat­
ed MM 1 .S cells run through SDS-PAGE and cut from a correspond-
ing area of the gel (50-70 kDa) revealed protein disulfide isom­
erase Al (PD1A1, protein disulfide isomerase precursor) as most 
abundant protein found only after treatment. Two other PDI 
family members, PDIA3 (protein disulfide isomerase precursor 
A 3) and PD1A4 (protein disulfide isomerase precursor A 4), were 
also only identified in treated samples (Supplementary Table S2).
Incubation of recombinant PDI with B-CCF642 with or with­
out prior CCF642 incubation followed by SDS-PAGE and biotin 
stain confirmed PDI as common target (Fig. 5C). B-CCF642 also 
covalently bound to recombinant PDIA3 but not to BSA used in 
the animal treatment formulation for its solubility-enhancing 
properties (Fig. 5C).To test whether CCF642 affects PDI function, 
we performed di-E-GSSG assays, which measure PDI's reducing 
capacity (17), and compared inhibition to known PDI inhibitors 
PACMA31 (22) and LOC14 (23). CCF642 at 1 μmol/L inhibited 
reduction of di-E-GSSG about as much as 100 μmol/L of LOC14 
or PACMA 31 (Fig. 5D). Accordingly, the anti-multiple myeloma 
activity against three exemplary multiple myeloma cell lines was 
most pronounced with CCF642 (Fig. 5E). These observations 
raised the question of how CCF642 inhibits PDI.
CCF642-PDI binding model
Computational docking argued against covalent binding to 
active site cysteine used by PACMA 31 and all other known 
covalently binding PDI inhibitors (22, 24), as CCF642 could not 
be approximated any closer than 5 Angstrom. The amino group of 
adjacent conserved functionally relevant lysine (25), with 2.8 
Angstrom came close enough to the carbonyl group of CCF642
to propose a covalent reaction (Fig. 5F). B-CCF642 binding 
studies on PDIA1 mutants targeting both active sites were con­
sistent with this computational hypothesis. Replacement of lysine 
with glutamic acid completely blocked, whereas the NH2 side 
chain containing glutamine allowed weak binding; replacement 
of cysteine with serine had no effect (Fig. 4G). Definitive crystal­
lographic binding studies are beyond the scope of this article but 
clearly needed since a covalent reaction with lysine would likely 
require its deprotonation and it is not known whether this occurs 
during PDFs redox reactions or upon entry of CCF642 into its 
enzymatic pocket. Computationally, additional non-covalent 
interactions were predicted between NO2 of the nitrothiophene 
moiety of CCF642 and the NH2 side chain of glutamine adjacent 
to lysine (Q402 in Fig. 5F). All PDI family members pulled out 
from multiple myeloma cells with B-CCF642 have NH2 side chain 
containing amino acids at that site, suggesting they may be
important for PDI activity and for binding of B-CCF642. Accord­
ingly, substitution of the NO2 group in CCF642 with COOH 
reduced anti-PDI activity (Fig. 6A) and binding to PDI as assessed 
by competition with B-CCF642 (Fig. 6B). To investigate whether 
the NO2 group might be released from CCF642 and inhibit PDI 
via S-nitrosylation, we incubated recombinant PDI with CCF642 
or S-nitrosogluthathione and tested for nitrosylated PDI using the 
biotin switch method (26). We found no evidence for s-nitrosyla­
tion of PDI with CCF642, whereas the positive control effectively 
caused this change (Fig. 6C). Furthermore, the bacterial SOS 
chromotest found no evidence for genotoxicity of CCF642 up to 
20 μmol/L with or without prior liver enzyme incubation (Fig. 
6D), arguing against nonspecific DNA toxicity, which could occur 
with NO2 release or other DNA toxic effects. The reaction between 
CCF642 and CGHCI< motifs of PDI family members therefore 
likely leaves CCF642 intact. The putatively novel mechanism of
Figure 3.
CCF642 has in vivo anti-multiple 
myeloma activity comparable with 
bortezomib. A, CCF642 and 
bortezomib significantly (log-rank 
test) extend survival in the aggressive 
5TGM1-luc∕C57BL∕KaLwRij mouse 
model of myeloma (6 males, 7 females 
per treatment group). B, in vivo 
imaging on day 23 confirms anti-
multiple myeloma activity of CCF642 
and bortezomib (BTZ) with 
significantly (Student t test) lower 
luminescence. Top, in vivo images; 
bottom, signal intensity. Error bars, 
SEM. C, weight of mice was not 
affected by treatments. D, results of 
blood draws from 5 separate male 
and female 5TGM1-luc-bearing 
C57BL∕KaLwRij mice after 2 and 
4 weeks of treatment, respectively 
(reference values). Error bars, SD.
PDI inhibition, higher potency than known PDI inhibitors, and 
favorable safety signals from NLBM, animal studies, and the 
bacterial genotoxicity screen warranted pursing the mechanism 
of antimyeloma action of CCF642 further.
Figure 4.
Growth in bortezomib (BTZ) does not 
cause CCF642 resistance. Six-month 
exposure to bortezomib followed 
by at least 3 days off increased the 
IC50 toward this drug in two multiple 
myeloma cell lines, whereas it did not 
increase IC50 for CCF642. The 
x-axis displays multiples of the IC50 in 
parent cells required to reduce trypan 
blue-negative cells at 72 hours for 
each drug as average of three 
independent experiments. Error 
bars, SD.
Acute ER stress with apoptosis-inducing calcium release in 
myeloma by CCF642
Treatment of myeloma cells with CCF642, PACMA 31, or 
LOC14 at doses in the upper clinically achievable range leads to 
accumulation of misfolded proteins in the ER as documented 
by dimerization of PERK via phosphorylation (3, 4) and 
oligomerization of IRE-lα (27), most pronounced after 
CCF642, but suggesting they may all be able to inhibit PDI 
in vivo (Fig. 7A). Increase of the proapoptotic unfolded protein 
response (UPR) mediator CHOP is evident within 30 minutes 
for all compounds but interestingly XBPl-s, a critical transcrip­
tion factor for mediating the adaptive UPR (3, 4), undergoes a 
time-dependent decline that correlates with PARP cleavage, 
suggesting it may be degraded by apoptotic enzymes along 
with misfolded protein sensors PERK and IRE-lα (Fig. 7A). To 
investigate whether XBP1 activation via unconventional splic­
ing of its cytoplasmic mRNA by dimerized IRE-lα is intact we 
performed RT-PCR (Fig. 7B). In these experiments, MM1.S cells 
were used, as it was known that despite baseline ER stress, 
spliced XBP1 mRNA is not detectable in them without exog­
enous stressors (28). CCF642 caused IREl-α dimerization 
within 15 minutes, peaking at 1 hour, and within 2 hours, 
spliced XBP1 mRNA could be detected confirming lREl-α 
dimers were functionally intact (Fig. 7B) and followed a similar 
time course as the other main ER stress sensor, PERK (Fig. 7C). 
Nuclear fractions demonstrated decrease of the transcription 
factor XBP-ls within 15 minutes compromising defense against 
ER stress, probably due to acute induction of apoptotic path­
ways by CCF642 (Fig. 7A and E). As kinetics of apoptotic 
pathway induction were faster than predicted for the transcrip­
tion factor CHOP, we hypothesized acute increase of misfolded 
proteins might trigger apoptosis-inducing release of ER calcium 
stores. Indeed, single-cell cytosolic calcium measurements in 
MM1.S and NLBM after 3 μmol/L CCF642 revealed selective 
increase in MM1.S that followed a similar time course as ER 
stress sensor (PERK, IREl-α) and apoptotic pathway kinetics, 
whereas NLBM did not respond noticeably with ER stress 
sensors (total PERK and IRE-lα antibodies yielded no signals, 
shown PERK is faint) and minimally cleaved caspase-3 (Fig. 
7B-D and F). BAPTA AM, a cell-permeable calcium chelator
dose, dependently delayed caspase-3 and PARP cleavage in 
MM1.S by CCF642 (Fig. 7E), suggesting calcium release con­
tributed to apoptosis.
Discussion
Here we report the discovery of a novel antimyeloma drug 
candidate with inhibitory function on the only enzyme family 
capable of folding disulfide-rich secreted proteins like antibodies 
through a mechanistically unbiased screening algorithm, which 
simulated key barriers to in vivo success.
Efficacy of lead CCF642 in a syngeneic mouse myeloma 
model (Figs. 2 and 3) comparable to fully optimized FDA- 
approved first-line proteasome inhibitor bortezomib (Fig. 3) 
confirms that an anti-multiple myeloma assay with highly 
simplified modeling of liver, non-hepatic clearance, and bone 
marrow (Figs. 1 and 2B) can identify promising drug candidates. 
CCF642 was one of three structurally distinct compounds from a 
30,335 small-molecule screening algorithm demonstrating 
desired anti-multiple myeloma activity without substantial 
bone marrow toxicity in this assay that we applied as low- 
throughput manual screen on 225 confirmed active anti-mul­
tiple myeloma small molecules. The two other compounds (Fig. 
2) were less convincing during pilot in vivo experiments, but this 
may in part be related to difficulties with their formulation 
(CCF1118) or lower potency (CCF1172). The described setup 
with lymphoid and myeloid growth factor secreting HS-5 bone 
marrow stromal cells as niche, documented to confer resistance 
not only to multiple myeloma (21, 29) but also to myeloid and 
other lymphoid cells (30-32), should be applicable to a variety 
of bone marrow cancers but would require adjustment for solid 
tumors. Compared with reported cancer-niche screens (33), 
growth in semipermeable inserts expands modeling options like 
simulation of non-hepatic clearance without disruption of cell 
contacts by transfer into drug-free media. Use of inserts further 
enables compartmentalized NLBM growth and inclusion of liver 
homogenate. Applied to chemical library compounds it will not 
mimic in vivo pharmacokinetic behavior but has the potential to 
enrich for agents with higher likelihood of in vivo activity by 
filtering for stability toward liver enzymes, ability to diffuse 
(through agarose and cell layers), and suppress cancer on niche 
with adjustable bolus-like or constant exposure. Our results 
suggest it may further enable selection of agents without sub­
stantial adverse effects on the bone marrow (Fig. 3D). If others 
confirm our findings and automation is achieved, it may
Figure 5.
PDI is a target of CCF642. A, biotinylated CCF642 (B-CCF642). B, streptavidin IHC confirms entry of B-CCF642 into the cytoplasm of MM1.S cells. C, CCF642 and B- 
CCF642 compete for binding to recombinant PDIA1, quantified by densitometry of immunoblot images normalized to background and PDI AB signals (left). 
The right immunoblot panel shows no evidence for covalent B-CCF642 binding to BSA after 30-minute incubation but to PDIA3. Ponceau S stain was used 
to document protein loading. D, time-dependent inhibition of di-E-GSSG reduction by PDI with CCF642 or known PDI inhibitors PACMA 31 and LOC14 
normalized to spontaneous di-E-GSSG reduction. E, reduction of trypan blue-negative cells at 72 hours in three multiple myeloma cell lines by CCF642 and known PDI 
inhibitors at up to 6.75 μmol∕L. F, electrostatic surface representation of CCF642 docked onto PDI (Protein Data Bank ID: 4EKZ) as predicted by Autodock 4. 
Energy minimization suggested covalent binding may occur to conserved lysine K401, where the carbonyl group of CCF642 is predicted to reach within 2.8 A of its 
amino group, whereas distances of 4.58 and 5.83 A between the oxygen atoms of the NO2 group of CCF642 and the NH2 group of glutamine 402 suggest 
noncovalent interaction could occur at this site. A similar situation is predicted for the other active site CGHCK motif and for other PDIs sharing this motif.
G, biotin stain and anti-His AB immunoblot after a 30-minute incubation with 5 μmol/L B-CCF642 of recombinant wild-type PDIA1 and mutants that have both active 
sites (a and a') mutated as indicated shows B-CCF642 binding is dependent on lysine but not on cysteine. All experimental results under this figure are 
representative of at least three independent experiments. Error bars, SD.
Figure 6.
The NO2 group of CCF642 is important for PDI inhibition but does not lead to S-nitrosylation or genotoxicity. A, structure of CCF642 analog with COOH instead of NO2 
(top), which is about 10× less potent than parent CCF642 in the di-E-GSSG PDI activity assay (bottom). B, CCF642-COOH competes with B-CCF642 for 
PDI binding but less potently than CCF642 by densitometric analysis (Fig. 5C). C, PDI was incubated with 10 μmol/L CCF642 or 10 mmol/L S-nitrosogluthathione for 1 
hour before processing according to the biotin switch method that exchanges S-nitrosylated sulfhydryl groups with biotin. D, SOS chromotest bacteria 
(ebpi, inc.) induce β-galactosidase in response to genotoxic stress and constitutively express alkaline phosphatase. The graph shows increase in β-galactosidase∕ 
alkaline phosphatase signals = SOS activity after 2-hour incubation at indicated doses for the genotoxic agent 4NQ0 and for 2AA, which becomes genotoxic 
after liver enzyme incubation. CCF642, with or without liver incubation, did not increase SOS activity over untreated control. Results are representative 
of three independent experiments. Error bars, SD.
streamline cancer drug discovery by reducing unsuccessful costly 
animal experiments.
Like many small molecules from diversity libraries, CCF642 has 
limited aqueous solubility, creating challenges when moving 
from in vitro to in vivo where higher volume of distribution 
requires administration of more concentrated drug. After standard 
solvents used for intravenous formulations failed to keep CCF642 
in solution, we explored albumin, an abundant plasma protein 
with hydrophobic and hydrophilic surfaces. Albumin is FDA- 
approved as carrier for paclitaxel in Abraxane and bovine as well as 
human albumin has been used in mice effectively for drug 
delivery (34, 35). Albumin-dissolved CCF642 could be given 
intravenously without injection reactions in mice, but for ease 
of administration, we chose the intraperitoneal route and saw 
promising efficacy without obvious toxicity. Albumin could gen­
erally be considered for clinical translation but we anticipate 
medicinal chemistry optimization will enable a less expensive 
formulation. Respective efforts will aim for crystallographic con­
firmation of the putatively novel interaction with PDI (Fig. 5F and 
G) to allow rational design and analog pharmacophore testing. 
The thiazolidinedione-like structure of CCF642 and its ability to 
increase cytosolic calcium in myeloma cells suggest special atten­
tion will need to be placed on liver, mitochondrial, and cardiac 
safety in the analog selection process. Preliminary and limited 
safety analyses of CCF642 in myeloma-bearing mice found no
evidence for liver toxicity or fluid accumulation anti-diabetic 
PPAR-activating thiazolidinediones can cause, but mild decrease 
of blood sugar (Fig. 3D) reinforces the need for vigilance and 
suggests a possible off-target effect of CCF642 will need to be 
investigated. Stable cytosolic calcium in NLBM cells after CCF642 
(Fig. 7D) argues against broad nonspecific mitochondrial toxicity 
but does not obviate the need for further investigation into 
possible effects of optimized analogs on liver or heart. Further­
more, asymptomatic increase of neutrophils in intraperitoneal 
albumin-CCF642-treated mice (Fig. 3D) suggests optimizing 
formulation to avoid delayed precipitation that may have sub- 
clinically irritated peritoneal membranes and investigating pos­
sible alternate mechanisms will be important in drug develop­
ment. Although the CCF642 scaffold raises outlined safety con­
cerns, our preliminary analyses suggest it may yield an optimized 
analog that satisfies safety mandates for clinical translation.
Success of the proteasome inhibitor bortezomib has estab­
lished protein homeostasis as valid target in oncology, especially 
for lymphoid malignancies (11, 36) but multiple myeloma 
remains incurable costing estimated 11,240 lives in 2015 in the 
United States (SEER). CCF642, consistent with its effect on 
proteostasis by PDI inhibition (Figs. 5 and 7), had potent activity 
in the submicromolar IC50 range on multiple myeloma and 
lymphoma cell lines while so far limited evaluations in myeloid 
neoplasia revealed more varied and less pronounced effects
Figure 7.
Acute ER stress with apoptosis-inducing calcium release in myeloma by CCF642. A, PDI inhibitors increase PERK dimerization by phosphorylation and IRE1-α 
oligomerization within 30 minutes in KMS-12-PE confirming accumulation of misfolded ER proteins. Proapoptotic ER stress signaling via CHOP induction is 
intact with all PDI inhibitors but XBP-1s, a transcription factor mediating adaptive ER stress responses, decreases in a temporal pattern that correlates with PARP 
cleavage, suggesting breakdown along with PERK and IRE1-α. PDI staining documents comparable loading. B, immunoblots and RT-PCR of MM1.S whole 
cell, nuclear, and cytoplasmic fractions show XBP1 splicing (s) of cytoplasmic unspliced (u) mRNA in response to CCF642 is intact and detectable about 1 hour after 
dimerization of IRE1-α peaks. Nuclear XBP1-s protein undergoes a decline that correlates with PARP cleavage (E) in this cell line as well. C, PERK dimers in 
MM1.S cells treated with CCF642 confirm increase of misfolded proteins in the ER of MM1.S cells after 15 minutes. D, MM1.S and NLBM cells were loaded with 
the intracellular calcium indicator Fura-2 AM, and cytoplasmic calcium concentration was continuously recorded following addition (arrow) of 3 μmol/L 
CCF642 or DMSO vehicle. Each trace is average calcium concentration in 86 to 89 cells. E, immunoblots show that pretreatment of MM1.S cells with intracellular 
calcium chelator BAPTA AM for 1 hour before 3 μmol/L CCF642 delayed caspase-3 and PARP cleavage. F, immunoblot of NLBM cells after CCF642 treatment 
reveals minimal increase in PERK dimers and minimal caspase 3 cleavage. Results are representative of at least three independent experiments per panel.
(Supplementary Fig. S3). The central role of PDI for ER produc­
tivity and stress reduction suggests exocrine cancers and histolo­
gies with high levels of ER stress should be tested in future studies. 
Two leading PDI inhibitors have remained preclinical so far; 
PACMA 31 covalently binds to active site cysteines of PDI and 
has shown promise in ovarian cancer (22), whereas LOC14 was 
found to have antiapoptotic function on nerve cells in a model of 
Huntington disease and binds noncovalently at nanomolar con­
centration but requires high micromolar doses for PDI inhibition 
in the insulin aggregation assay (23), which measures its reducing 
potency (24). To date, no reliable method for measuring PDI 
activity in cells has been described and in intro assays used in drug 
discovery poorly reproduce PDI physiology where cysteine oxi­
dation, reduction, and isomerization of disulfide bonds has to be 
accomplished in short sequence and is influenced by additional 
enzymes, like Erol-α (37) that restore oxidative potential of PDI 
required for immunoglobulin folding (5). Therefore, current in 
vitro PDI activity assays mainly establish that a drug candidate can 
affect PDI function but not how effectively its versatile enzymatic 
potential is impaired in vivo or how profoundly restoration by 
Erol-α is affected. We chose the most sensitive in vitro PDI activity 
assay to quantify inhibition and then evaluated whether the most 
upstream expected consequence of PDI inhibition occurred in 
cells, sensing of misfolded ER proteins by PERK and IREl-α. 
CCF642 was more potent than known PDI inhibitors in the in 
vitro assay against myeloma cells (Fig. 5) and when assessed for 
ability to increase misfolded ER proteins in multiple myeloma 
cells, but the latter experiments that used doses in the upper 
range of generally clinically achievable (3 μmol/L) suggested that 
all PDI inhibitors may reach their target in vivo (Fig. 7A). For 
CCF642, the only PDI inhibitor where this dose was above the 
IC50 against multiple myeloma cells and against PDI in vitro, this 
was followed by acute induction of apoptosis, faster than expected 
from induction of the proapoptotic ER stress mediator CHOP. 
Further studies suggested that calcium release, possibly from rapid 
accumulation of misfolded ER proteins, was at least partially 
responsible (Fig. 7). Detailed studies on the mechanism of 
calcium release by CCF642 in multiple myeloma are beyond the 
scope of this article but might reveal additional targets or inter­
ference with interaction of PDI with calcium-regulating proteins 
like calreticulin (38).
In summary, results suggest a straightforward assay that simu­
lates important barriers to in vivo success of anti-multiple mye­
loma compounds can yield candidates promising for clinical 
translation. While its first lead may act through mechanisms in 
addition to PDI inhibition, it is so far the most promising anti-
multiple myeloma PDI-inhibiting compound. Fully defining its 
interaction with PDI through crystallography may enable devel­
opment of optimized specific PDI inhibitors with potentially 
broader oncology application.
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